clinical trial · NCT07232030
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
CVRx, Inc.·N/A·recruiting·n = 2,500
Heart FailureHeart Failure NYHA Class IIHeart Failure NYHA Class IIIBarostim SystemUsual care medical management
brief summary
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).
started
Apr 1, 2026
primary completion
Jan 1, 2033
completion
Jan 1, 2033
last updated
Apr 27, 2026
official title
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure (BENEFIT-HF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol